develops the product PrC-210, that can prevent damage to organs from oxidative stress and ischemic reperfusion injury. This is applicable in medical indications, such as organ  transplantation, radiation protection, myocardial infarction, stroke, sepsis and protection from cytokine storm. The company is focusing on those medical indications where the product can be brought to markets with highest probability of success and is looking for global product approval.